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Abstract
Background: The conserved CD4 binding site (CD4bs) on HIV-1 gp120 is a major target for vaccines. It is a priority
to determine sites and structures within the CD4bs that are important for inclusion in vaccines. We studied a
gp120 pocket penetrated by W100 of the potent CD4bs monoclonal antibody (mab), b12. We compared HIV-1
envelopes and corresponding mutants that carried blocked W100 pockets to evaluate whether other CD4bs mabs
target this site.
Findings: All CD4bs mabs tested blocked soluble CD4 binding to gp120 consistent with their designation as
CD4bs directed antibodies. All CD4bs mabs tested neutralized pseudovirions carrying NL4.3 wild type (wt)
envelope. However, only b12 failed to neutralize pseudoviruses carrying mutant envelopes with a blocked W100
pocket. In addition, for CD4bs mabs that neutralized pseudovirions carrying primary envelopes, mutation of the
W100 pocket had little or no effect on neutralization sensitivity.
Conclusions: Our data indicate that the b12 W100 pocket on gp120 is infrequently targeted by CD4bs mabs. This
site is therefore not a priority for preservation in vaccines aiming to elicit antibodies targeting the CD4bs.
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Findings
The conserved CD4 binding site (CD4bs) on HIV-1 gp120
is a major target for the development of vaccines that aim
to elicit neutralizing antibodies effective against diverse
HIV-1 strains. It is, therefore, important to define sites
and structures within the CD4bs that will need to be pre-
served in vaccines for the induction of neutralizing antibo-
dies. The CD4 binding site (CD4bs) monoclonal antibody
(mab), b12, targets a pocket on HIV-1 gp120 as part of its
binding site. Thus, the organic rings of b12 W100 pene-
trate the pocket located immediately downstream from
the CD4 binding loop (Figure 1). We showed previously
that the presence of a combination of an arginine at resi-
due 373 and a glycan at N386 appears to block the pocket
and confer robust resistance to b12 for all five primary
HIV-1 envelopes tested [1]. Even the highly sensitive
envelope of the T-cell line adapted NL4.3 strain became
resistant when carrying the R373/N386 glycan combina-
tion. Single substitutions at 373 or that abrogate the glycan
at N386 also affect sensitivity to b12 neutralization (our
unpublished data and refs [2,3]). However, these changes
(in the absence of the R373/N386 glycan combination) are
frequently modest and envelope dependent. Here, we have
investigated whether the combination of an arginine at
residue 373 and a glycan at N386 (which confers resis-
tance to b12) affects the sensitivity of neutralization by
other CD4bs mabs.
We investigated 15 mabs that block sCD4 binding to
gp120 including the potent neutralizing human mabs,
b12 [4], HJ16 [5], VRC01 [6,7] and VRC03 [7] (Table 1).
Mabs were selected for testing based on two criteria.
First, we included mabs previously defined as targeting
the CD4bs by their capacity to block gp120: CD4 binding
or by crystallization as a complex with gp120. Second, we
used CD4bs mabs that were available in sufficient quanti-
ties for the neutralization assays described. These
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UK Centre for AIDS Reagents, the Vaccine Research
Center, NIH and from other sources (Table 1). We first
confirmed that each of the mabs under investigation
blocked sCD4 binding to recombinant gp120 in ELISA
assays (Additional File 1: Figure 1). We next tested the
capacity of each mab to neutralize NL4.3 wt and NL4.3
T373R (which combines R373 with the glycan already
present at N386). NL4.3 is ideal for investigating whether
mutation of the W100 pocket affects neutralization since
it is highly sensitive to b12 and to each of the CD4bs
mabs investigated here. Neutralization assays were done
using pseudovirions carrying envelopes from NL4.3wt
and NL4.3 T373R (NL4.3-R). HeLa TZM-bl cells were
used as targets, and residual infectivity was assessed by
measuring luciferase activity [8]. We found that neutrali-
zation of NL4.3 by each of the mabs was unaffected or
only weakly affected by the R373/N386 glycan combina-
tion (Figure 2). Briefly, NL4.3-R appeared marginally
more sensitive to mab 15e, yet modestly more resistant
to 1595. In addition, the T373R/N386 glycan combina-
tion conferred increased sensitivity to the CD4i mab 17b,
perhaps indicating a modest shift in envelope conforma-
tion towards the CD4-bound form [9].
The NL4.3 envelope is derived from a T-cell line
adapted HIV-1 and may not accurately represent the
structures of primary envelopes in vivo. We, therefore,
evaluated whether mutation of the W100 pocket
affected the sensitivity of primary envelopes. For this
experiment, we used AD8 [10], JR-CSF, and JRFL [11]
envelopes that were derived from limited culture pri-
mary isolates as well as LN40 and B33 that were
Figure 1 Proximal gp120 residues T373 and N386 (red) surround the pocket penetrated by the organic rings of b12’s W100 (yellow).
The longer side chain of R373 in combination with the glycan (orange) at N386 may block the pocket and prevent b12 (green) binding.
Table 1 CD4 binding site monoclonal antibodies
investigated
Mab Species Epitope Source Ref.
b12 human CD4bs Polymun Sci. GmbH [4]
VRC01 NIH VRC
1.[ 6 ]
VRC03 NIH VRC.
HJ16 Humabs Inc. [5]
F105 NIH AIDS Rea. Pr.
2 [19]
654-D NIH AIDS Rea. Pr. [20]
15e UK/EU CFAR
3 [21]
M14 UK/EU CFAR [22]
Gp68 UK/EU CFAR [23]
1027 Dr Zolla-Pazner
1008 Dr Zolla-Pazner
1570 Dr Zolla-Pazner [24]
1595 Dr Zolla-Pazner [24]
1599 Dr Zolla-Pazner [24]
ICR39.13 rat UK/EU CFAR [25]
17b human CD4i NIH AIDS Rea. Pr. [9]
1. NIH Vaccine Research Center.
2. NIH AIDS Reagent Program.
3. Programme EVA Centre for AIDS Reagents, UK.
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an AIDS patient, respectively [12]. We tested the sensi-
tivity of envelopes with and without a mutated W100
pocket to neutralization by the potent and broad CD4bs
mabs, VRC01 and VRC03 and compared with sensitivity
to b12 (Figure 3). For AD8, JR-CSF and JR-FL, the
mutated envelopes carried a single substitution to R373
to make the R373/N386 glycan combination. For B33, a
double substitution introduced R373/N386; while for
LN40 (which naturally carries R373/N386), we substi-
tuted K373/D386 to reflect t h es e q u e n c eo ft h eB 3 3
envelope. For all five of these primary envelopes, the
Figure 2 Neutralization of pseudovirions carrying either NL4.3wt or NL4.3 T373R envelopes. NL4.3 T373R carries a blocked W100 pocket.
Env+ pseudovirions were treated with serial dilutions of each mab and residual infectivity evaluated on HeLa TZM-bl cells using luminescence
readouts [8]. Mab dilutions are recorded as μg/ml except for gp68 and ICR39.13, which are hybridoma supernatant dilutions. Each data point
shown was obtained from averaging readings obtained from two independent neutralization tests each with duplicate points.
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in sensitivity to b12 as expected (Figure 3, left panels).
In contrast, for both VRC01 and VRC03, a mutated
W100 pocket failed to confer more than minor shifts in
neutralization sensitivity. The mutated JR-FL envelope
conferred a small shift to increased resistance to VRC01,
while JR-CSF became modestly more resistant to
VRC03. In contrast, B33 and LN40 wt and mutant
envelopes were resistant to VRC03. Together, our data
show that the combination of R373 and the N386 glycan
Figure 3 Neutralization of pseudovirions carrying primary HIV-1 envelopes with and without mutated W100 pockets. For AD8, JR-CSF
and JR-FL, a single substitution introduced R373 to combine with the N386 glycan already present in these envelopes to form the R373/N386
glycan combination to block the W100 pocket. The wild type LN40 envelope already carries the R373/N386 glycan combination and was
mutated to change both these residues to K373/D386. The reciprocal substitutions in B33 converted K373/D386 to R373/N386. All envelopes
carrying a putative closed W100 pocket were substantially more resistant to mab b12, but remained sensitive to VRC01 and VRC03. Some
modest shifts in sensitivity were observed and are discussed in the main text. Each data point shown was obtained from averaging readings
obtained from two independent neutralization tests each with duplicate points.
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tion by 14 CD4bs mabs contrasting with robust resis-
tance consistently conferred for b12.
Recently, further CD4bs mabs, e.g. 3BNC60 [13] and
VRC-PG04 [14] have been reported [13-15]. Like
VRC01, VRC03, and HJ16 (studied here), they were
derived from so called ‘elite neutralizers’,H I V - 1 +s u b -
jects who carried potent neutralizing antbodies active
against diverse viral strains. These new mabs are highly
potent and have binding specificities that focus on simi-
lar gp120 residues to that of VRC01 [6], which (as con-
firmed here) does not penetrate the W100 pocket on
gp120. The crystal structure of mab 3BNC60 verifies a
structure where predicted gp120 contact residues are
conserved with those of VRC01 [13], while a structure
of mab VRC-PG04 complexed with a gp120 core shows
the same for that mab and confirms no interaction with
the W100 pocket on gp120. Diskin et al. also reported
that NIH45-46 conferred even more potent neutraliza-
tion than VRC01. However, the increased potency of
this mab was due to increased contact with the gp120
inner domain and bridging sheet determinants without
targeting the W100 pocket [16].
In summary, we investigated whether the W100 pocket
o ng p 1 2 0( ac r i t i c a lt a r g e tf o rm a bb 1 2 )i sr e q u i r e df o r
HIV-1 neutralization by other CD4bs mabs. We found
that neutralization of pseudovirions carrying primary or
T-cell line adapted HIV-1 envelopes was either unaf-
fected or only marginally shifted by the presence of a
mutated W100 pocket. These observations contrasted
with neutralization by b12, which was severely curtailed
by the presence of a mutated W100 pocket for all six
HIV-1 envelopes tested. Our data indicate that the W100
pocket on gp120 is not a frequent target among CD4bs
mabs and is not required for potent neutralization of
diverse primary strains of HIV-1 via the CD4bs.
Availability of supporting data
The data sets supporting the results of this article are
available in the Dryad repository http://dx.doi.org/
10.5061/dryad.66h5g23t.
Additional material
Additional file 1: Figure 1. Inhibition of CD4 binding to gp120. ELISAs
were carried out to confirm that CD4bs mabs blocked sCD4 binding to
gp120. For human mabs (except for gp68), serial (0-8 μg/ml) antibody
dilutions were added to saturating immobilized amounts of IIIB gp120
(Immunodiagnostics Inc.) captured with a sheep anti-gp120 C-terminal
peptide (Alto Bio Reagents Inc.). Appropriate sCD4 dilutions were then
added and bound sCD4 detected using mouse mab, OKT4, followed by
an anti-mouse IgG-HRP conjugate (Thermo Scientific Inc.). Mabs gp68
and ICR39.13 were in the form of hybridoma culture supernatant and
were added at 1:2 to 1:16 dilutions. ICR39.13 is a rat antibody and was
evaluated by competition with PRO542 (CD4-IgG) [17], followed by and
ant-human IgG-HRP conjugate. All mabs designated as binding the
CD4bs blocked sCD4 binding to recombinant gp120. Most blocked sCD4
highly efficiently, although neither VRC03 nor F105 was particularly
effective. Since the structures of VRC03 and F105 bound to gp120
irrevocably prove their specificity for the CD4bs [14,18], the reasons for
weaker sCD4 inhibition are unclear. We also tested the CD4i mab, 17b, as
a control. As expected, this mab failed to block sCD4 binding to gp120.
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